Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06659640 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
A Phase 1 study of Hereditary Hemorrhagic Telangiectasia, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 8
- Study locations
NCT06659640 is a Phase 1 study of Hereditary Hemorrhagic Telangiectasia that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 120 participants, below the 1,773-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT06659640, a Phase 1 study of Hereditary Hemorrhagic Telangiectasia, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALN-6400
Study Locations (8)
Other
- Clinical Trial Site - Mount Royal
- Clinical Trial Site - Toronto
- Clinical Trial Site - Bordeaux
- Clinical Trial Site - Bron
- Clinical Trial Site - Homburg
- Clinical Trial Site - L'Hospitalet de Llobregat
California
- Clinical Trial Site - Cypress
Massachusetts
- Clinical Trial Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-11-07 |
| Est. Completion | 2028-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06659640
The ClinicalTrials.gov registry entry for NCT06659640 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,773-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (93% lower). The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06659640 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06659640 about?
NCT06659640 is a clinical study titled "A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)". The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
What is the current status of trial NCT06659640?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-11-07. Estimated completion is 2028-06-22.
What conditions does trial NCT06659640 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia.
What interventions are being tested in trial NCT06659640?
The interventions under investigation include: Placebo (DRUG), ALN-6400 (DRUG).
Who is sponsoring clinical trial NCT06659640?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06659640 being conducted?
This trial has 8 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
COMPLETED · Phase 1
-
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
COMPLETED · Phase 1
-
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
RECRUITING
-
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING
-
Ultra-low-dose Chest CT for HHT
ACTIVE NOT RECRUITING
-
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.